{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'Pl: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'definition of what constitutes a negative biopsy, refer to section 7.1: Prostate Biopsy.', 'Subjects who drop out of the study due to disease progression, death, or limiting toxicity', 'or individual choice will be considered as failures in estimating the negative repeat', 'biopsy rate. Similarly, patients not undergoing repeat biopsy (for any reason) after', 'treatment with apalutamide will be considered as failures in estimating the negative', 'repeat biopsy rate. Patients who have not received at least one dose of apalutamide', 'will be replaced and not considered in determining the negative repeat biopsy rate. We', 'will use a 1-sample chi-square test to compare the proportion with a negative repeat', 'biopsy to the null hypothesis value of 20% (above). The 95% confidence interval (CI) of', 'the primary endpoint estimate will be computed.', 'Secondary endpoints will include: exit from active surveillance due to pathologic', 'progression or otherwise at 2 years, the receipt of local treatment for prostate cancer at', '2 years, local treatment free survival, PSA progression free survival (PFS) at 2 years,', 'radiographic disappearance of MRI detectable prostate cancer following treatment (only', 'in patients with baseline MRI), quality of life, safety and changes in exploratory', 'biomarkers (see protocol section 1.4) pre- and post-treatment.', 'For both cohorts, the exit rate (all cause and due to pathologic progression),', 'percent of men undergoing local treatment and PSA progression rate will be computed', 'along with its 95% CI at the two year time point (i.e. Day 730 visit). The local treatment', 'free survival and PSA PFS will be estimated using Kaplan-Meier methods and 95% CI', \"will be estimated using Greenwood's formula. 93 PSA PFS will be censored at the time of\", 'local therapy. PSA progression will be defined by the PCWG2 criteria (i.e. confirmed', 'rising PSA 2 ng/mL at least one week apart).', 'We will characterize toxicity as percentage by type and grade. Changes in quality', 'of life (as assessed by the FACT-P and SF-36 instrument scores) and changes in', 'exploratory biomarkers pre- and post-treatment will be assessed using paired t-test or', 'signed-rank test for continuous variables, or McNemar chi-square tests for categorical', 'variables. Baseline exploratory biomarker levels/values and change in exploratory', 'biomarkers pre-/post-treatment will be correlated with the primary endpoint using chi-', 'square tests and logistic regression, and with secondary endpoints using proportional', 'hazards models, Kaplan-Meier methods and log-rank tests.', '70', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'References:', '1.', 'Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for', 'patients with progressive prostate cancer and castrate levels of testosterone:', 'recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of clinical', 'oncology : official journal of the American Society of Clinical Oncology 2008;26:1148-59.', '2.', 'Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that', 'predicts metastasis following radical prostatectomy in an at risk patient population. The', 'Journal of urology 2013;190:2047-53.', '3.', 'Klein EA, Yousefi K, Haddad Z, et al. A genomic classifier improves prediction of', 'metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer', 'patients managed by radical prostatectomy without adjuvant therapy. European urology', '2015;67:778-86.', '4.', 'Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer', 'genomic classifier that predicts early metastasis following radical prostatectomy. PloS one', '2013;8:e66855.', '5.', 'Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX', 'prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC', 'genomics 2013;14:690.', '6.', 'Cooperberg M, Simko J, Falzarano S, et al. Development and validation of the biopsy-', 'based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate', 'cancer to improve patient selection for active surveillance. American Urological', 'Association Meeting; 2013; San Diego, CA.', '7.', 'Carver BS, Bianco FJ, Jr., Scardino PT, Eastham JA. Long-term outcome following', 'radical prostatectomy in men with clinical stage T3 prostate cancer. The Journal of urology', '2006;176:564-8.', '8.', 'Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and', 'survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive', 'patients: long-term results. The Journal of urology 2004;172:910-4.', '9.', 'Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality', 'in a randomized European study. The New England journal of medicine 2009;360:1320-8.', '10.', 'Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized', 'prostate-cancer screening trial. The New England journal of medicine 2009;360:1310-9.', '11. Carter HB. Active surveillance for prostate cancer: an underutilized opportunity for', 'reducing harm. J Natl Cancer Inst Monogr 2012;2012:175-83.', '12.', 'Newcomb LF, Brooks JD, Carroll PR, et al. Canary Prostate Active Surveillance Study:', 'design of a multi-institutional active surveillance cohort and biorepository. Urology', '2010;75:407-13.', '13.', 'Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer:', 'an update of the Johns Hopkins experience. Journal of clinical oncology : official journal of', 'the American Society of Clinical Oncology 2011;29:2185-90.', '14.', 'Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active', 'surveillance cohort of patients with prostate cancer. Journal of clinical oncology : official', 'journal of the American Society of Clinical Oncology 2015;33:272-7.', '71', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}